Abstract: A wireless communication system allows a handover operation to a base station communicating through a plurality of frequency bands. The mobile terminal includes a communication unit adapted to perform communication with any of the base stations through a plurality of frequency bands. The communication unit of the base station notifies, when communication through a plurality of frequency bands is possible, a mobile terminal about information directed to identifying a main frequency band from relevant frequency bands in a manner allowing discrimination from one or more frequency bands other than the main frequency band. The communication unit of the mobile terminal determines that, upon receiving information directed to identifying a main frequency band from the second base station during having communication connection with the first base station, that the frequency band identified by the relevant information is a subject of handover towards the second base station.

Abstract: A base station apparatus in the present invention includes a terminal-specific control channel generation unit that generates terminal-specific control channels mapped in a terminal-specific control channel region that is configured specifically to the terminal apparatus and that is constituted by a prescribed number of resource block pairs and transmitted. If a number of candidate specific control channels monitored by the terminal apparatus is smaller than or equal to a number of resource block pairs in the terminal-specific control channel region at each aggregation level, which indicates a number of the enhanced control channel elements used in each of the terminal-specific control channels, each of the candidate terminal-specific control channels corresponds to a different resource block pair in the terminal-specific control channel region. The terminal-specific control channels are mapped in one of the candidates.

Abstract: The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.

Abstract: A mobile station apparatus transmits in a subframe, to a base station apparatus, Hybrid Automatic Repeat Request (HARQ) control information and channel state information on the indicated one physical uplink control channel resource, the HARQ control information and the channel state information being transmitted using one of a first processing method of coding and a second processing method of coding, the one of the first processing method of coding and the second processing method of coding being applied on the basis of whether a sum of a number of bits of the HARQ control information and a number of bits of the channel state information exceeds a second predetermined value.

Abstract: A liquid crystal display device 10 includes an LED unit 30, a liquid crystal panel 11, a light guide plate 16, a chassis 14, and a frame 13. The LED unit 30 includes an LED 17 and an LED board 18. The light guide plate 16 arranged such that a light entrance surface 16b faces the LED 17. The frame 13 is fixed to the chassis 14. The frame 13 and the chassis 14 hold the liquid crystal panel 11 and the light guide plate 16 therebetween. The frame 13 includes a panel holding portion 13a and a sidewall portion 13b. The panel holding portion 13a holds the liquid crystal panel 11 from the display surface 11a side. The sidewall portion 13b continues from the panel holding portion 13a and extends on the light entrance surface 16b side. The frame 13a includes a through hole 40 that runs through the sidewall portion 13a.

Abstract: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: Provided is a display device characterized in that a display area can be prevented from appearing darker when the position of light-shielding sections are moved, while the control of voltages applied to electrodes is simplified. In the case where electrodes to which a specific voltage is applied are changed from a first electrode group (e.g., 52a) to a second electrode group (e.g., 52b, 58a, 58b), the voltage applied to the first electrode group is switched from the specific voltage to a reference voltage first, and thereafter, the voltage applied to the second electrode group is switched from the reference voltage to the specific voltage.

Abstract: A backlight device 12 includes LEDs 17, a light guide plate 16, a chassis 14, and a light source mounting member 30. The light guide plate 16 included a front surface configured as a light exit surface 16a, a rear surface configured as an opposite surface 16c, and two side surfaces configured as light entrance surface 16b. The light guide plate 16 is arranged such that the light entrance surface 16b are opposite light emitting surfaces 17a of the LEDs 17 and configured to guide light from the LEDs 17 toward the light exit surface 16a. The chassis 14 includes a plate-like portion 14a arranged on an opposite surface 16c side of the light guide plate 16. The light source mounting member 30 on which the LEDs 17 are mounted includes at least one bottom plate 30a including a front surface and a rear surface. The front surface is in surface-contact with a rear surface of the plate-like portion 14a. At least one portion of the rear plate surface is exposed to an external side.

Abstract: The present invention provides a display panel that exhibits increased light use efficiency and decreased occurrence of display anomalies. The display panel includes substrates; a light modulating layer that contains shape-anisotropic members that rotate according to the direction of an electric field and that controls the transmittance of incident light by changing the area projected onto the substrates by the shape-anisotropic members; and supporting members that support the shape-anisotropic members and are rotatably connected thereto.

Abstract: There is provided a broadcast receiving terminal that includes a reception unit, a display unit, and a reservation unit. The reception unit receives, over a network, content information, the content information including trailer information and reception reservation information. The display unit displays trailer content. The reservation unit reserves reception of the broadcast program.

Abstract: A display device includes a panel laminated body including a panel laminated body including a plurality of panels stacked together, flexible printed circuit boards each being connected to a corresponding one of respective short sides of the plurality of panels disposed in one of side portions of the panel laminated body, and an extension portion formed in at least a part of the flexible printed circuit boards so as to extend outwardly from a side area of the panel laminated body in a short-side direction of the panels in the side area. At least a pair of the extension portions is electrically connected together in a state where the pair of the extension portions is superimposed on each other and is folded in the side area of the panel laminated body.

Abstract: This light emitting device is provided with: a light emitting element which emits excitation light; and a far-red phosphor which is excited by the light of the light emitting element and emits light that has a peak wavelength within the range of 700-800 nm. The far-red phosphor has a median diameter within the range of 1-20 ?m.

Abstract: A display device includes a first cabinet to which a display panel is attached and a second cabinet to which a light source is attached. The first cabinet and the second cabinet are assembled with an optical member, which diffuses light from the light source, held between the cabinets. The optical member includes a first optical member having relatively large weight and a second optical member having relatively small weight. The first optical member is pressed by the top of a projection provided in at least one of the first cabinet and the second cabinet.

Abstract: In first and second display devices (10, 20) both during pause drive (intermittent drive), an instantaneous increase in consumption power is suppressed by means of a configuration to perform control such that the scanning period in one of the two display panels is inserted during the scanning-stopped period in the other display panel, namely during the drive operation (for writing into the pixel circuit) of one of the two display panels, the drive operation (for writing) of the other display panel is not performed. Accordingly, even when a limit value of a current supply capability of a battery is low, the display device can be driven, so that a battery service life is prolonged and the operable time of a portable terminal (100) at the time of driving by the battery is increased.

Abstract: A self-propelled cleaner (1), i.e., a self-propelled electronic device, includes a temperature measurement unit (63) that measures an ambient temperature during self-propelled operation, a temperature decision unit (521) that decides whether the measured ambient temperature is equal to or more than a set value, and an abnormal temperature notification unit (522) that externally reports abnormal temperature information indicating that the measured ambient temperature is equal to or more than the set value if the measured ambient temperature is decided to be equal to or more than the set value.

Abstract: The present invention provides an electrophotographic photoreceptor comprising a multilayered photosensitive layer or a monolayer photosensitive layer, wherein the multilayered photosensitive layer comprises at least a charge generation layer containing a charge generation material and a charge transport layer containing a charge transport material that are stacked on a conductive substrate in this order, and the monolayer photosensitive layer contains a charge generation material and a charge transport material that is stacked on a conductive substrate, wherein the electrophotographic photoreceptor contains 5 to 17 wt % of fluorine resin fine particles and their aggregates with respect to all photoreceptor components in a surface layer of the photoreceptor, wherein the fluorine resin fine particles are 0.1 to 0.

Abstract: This semiconductor device (100) includes a substrate (10) and a TFT which is provided on the substrate. The TFT includes a gate electrode (12), an oxide semiconductor layer (14) which faces the gate electrode, source and drain electrodes (16, 18) which are connected to the oxide semiconductor layer, and an insulating layer (22) which contacts at least partially with the source and drain electrodes. The insulating layer (22) includes a lower region (22b) which contacts at least partially with the source and drain electrodes and an upper region (22a) which is located over the lower region. The lower region (22b) has a higher hydrogen content than the upper region (22a).

Abstract: The present invention is directed to compositions comprising the HCV NS3/4A inhibitor, (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopro-pyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxamide, or a pharmaceutically acceptable salt thererof, an oral absorption enhancing polymer, and, optionally, a surfactant. The present invention is also directed to solid dispersions and pharmaceutical compositions containing or made from these compositions, and the methods for making these solid dispersions and pharmaceutical compositions.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.